Momenta Pharma (MNTA)
$24.65 2.55 (9.38%)
16:59 EDT MNTA Stock Quote Delayed 20 Minutes
Previous Close $27.20
Market Cap 1.91B
PE Ratio -17.99
Volume (Avg. Vol.) 1.44M
Day's Range 24.04 - 26.51
52-Week Range 9.51 - 34.83
Dividend & Yield N/A (N/A)
MNTA Stock Predictions, Articles, and Momenta Pharma News
- From InvestorPlace
- From the Web
Thinking about buying Mylan stock? You may not want to just yet. It's toying with a support line that, if it snaps, could open the selling floodgates.
Teva Pharmaceutical desperately needs a new CEO - and a new strategy to boot - to stop the steady decline in TEVA stock.
Teva Pharmaceutical (TEVA) has more upside than most investors realize. Look past the Copaxone debacle, and TEVA stock is promising.
Despite Teva's (TEVA) gains on earnings and rival delays, TEVA stock is still facing impassive sentiment and broad selling pressure.
Small caps are well positioned to benefit from a reduction in tax rates. Consider these 5 stocks to buy on a tax rate reduction
From Market News Video
Investors in Momenta Pharmaceuticals Inc (MNTA) saw new options become available this week, for the May 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MNTA options chain for the new May 15th contracts and identified one put and one call contract of particular interest.
From Simply Wall St
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and mining exploration companies often lose money for years<div><a class="permalink" href="https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mnta/momenta-pharmaceuticals/news/were-not-very-worried-about-momenta-pharmaceuticalss-nasdaqmnta-cash-burn-rate/">Read More...</a></div>
Navellier RatingsPowered by Portfolio Grader